Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: A possible link to insulin resistance?

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 4, 1997, Pages 1147-1153

  Ek, Ingvar ^a   Arner, Peter ^a   Bergqvist, Agneta ^a   Carlström, Kjell ^a   Wahrenberg, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BUCLADESINE; CLONIDINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOBUTAMINE; ETHINYLESTRADIOL PLUS NORETHISTERONE; FORSKOLIN; INSULIN; LIPOPROTEIN LIPASE; NORADRENALIN; ORAL CONTRACEPTIVE AGENT; ORTHONETT NOVUM; TERBUTALINE SULFATE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERANDROGENISM; INSULIN RESISTANCE; LIPOLYSIS; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; SUBCUTANEOUS FAT;

ADIPOCYTES; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; ADULT; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOLYSIS; POLYCYSTIC OVARY SYNDROME; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, BETA; REFERENCE VALUES;

EID: 0030972696     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.4.1147     Document Type: Article

References (44)

1. Burghen G, Givens J, Kitabachi A. 1980 Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 50:113-116.
2. Chang J, Nakamura R, Judd L, Kaplan S. 1983 Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 57:356-359.
3. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. 1987 Characterization of groups of hyperandrogenic women with acanthosis nigrans, impaired glucose tolerance and/or hyperinsulinemia. J Clin Endocrinol Metab. 65:499-507.
4. Dahlgren E, Johansson S, Lindstedt G, et al. 1992 Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 57:505-513.
5. Dahlgren E, Jansson PO, Johansson S, Lapidus L, Odén A. 1992 Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand. 71:599-604.
6. DeFronzo RA, Ferrannini E. 1991 Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:173-194.
7. Tchernof A, Despres JP, Belanger A, et al. 1995 Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism. 44:513-519.
8. Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. 1984 Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J. 288:1401-1404.
9. Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. 1990 Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 39:897-901.
10. Seidell JC, Cigolini M, Charzewska J, et al. 1990 Androgenicity in relation to body fat distribution and metabolism in 38-year-old women-the European Fat Distribution Study. J Clin Epidemiol. 43:21-34.
11. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Björntorp P. 1991 Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes. 40:123-128.
12. Peiris AN, Drucker AWD, Kissebah AH. 1989 The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women. J Clin Endocrinol Metab. 68:715-720.
13. Arner P. 1993 Regulation of adipose tissue lipolysis, importance for the metabolic syndrome. Adv Exp Med Biol. 334:259-267.
14. 3-adrenoceptor in man. Br J Pharmacol. 110:929-936.
15. 3-adrenoceptors in obesity. J Clin Invest. 95:1109-1116.
16. 2-adrenoceptors. Diabetologia. 37:428-435.
17. Reynisdottir S, Ellerfeldt K, Wahrenberg H, Lithell H, Arner P. 1994 Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest. 93:2590-2599.
18. Carlström K, Gershagen S, Rannevik G. 1987 Free testosterone and testosterone/SHBG index in hirsute women: a comparison of diagnostic accuracy. Gynecol Obstet Invest. 24:256-261.
19. Brody S, Carlström K, Lagrelius A, Lunell NO, Rosenborg L. 1983 Serum levels of 4-androstene-3,17-dione in menstruating and postmenopausal women. Evaluation of a radioinnunoassay and correlation to bone mineral content and endometrial pathology. Acta Obstet Gynecol Scand. 62:531-534.
20. Carlström K, Brody S, Lunell NO, et al. 1988 Dehydroepiandrosterone sulfate and dehydrepiandrosterone in serum: age and sex-related differences. Maturitas. 10:297-306.
21. Arner P, Arner O, Östman J. 1973 The effect of local anaesthetic agents on lipolysis by human adipose tissue. Life Sci. 13:161-169.
22. Rodbell M. 1964 Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem. 239:375-380.
23. Di Girolamo MS, Meddlinger S, Fertig JW. 1971 A simple method to determine fat cell size and number in four mammalian species. Am J Physiol. 221:850.
24. Hirsch J, Gallian E. 1968 Methods for determination of adipose cell size and number in man and animals. J Lipid Res. 9:110-119.
25. Wahrenberg H, Lönnqvist F, Arner P. 1989 Mechanisms underlying regional differences in lipolysis in human adipose tissue. J Clin Invest. 84:458-467.
26. Östman J, Arner P, Kimura H, Wahrenberg H, Engfeldt P. 1984 Influence of fasting on lipolytic response to adrenergic agonists and on adrenergic receptors in subcutaneous adipocytes. Eur J Clin Invest. 14:383-391.
27. Munson P, Rodbard D. 1980 LIGAND: a versatile computerized approach for characterization of ligand binding systems. Anal Biochem. 107:220-239.
28. Arner P, Hellmer J, Wennlund A, Östman J, Engfeldt P. 1988 Adrenoceptor occupancy in isolated human fat cells and its relationship with lipolysis rate. Eur J Pharmacol. 146:45-56.
29. 3-adrenoceptor in man. J Clin Invest. 95:2239-2245.
30. Rebuffé-Scrive M, Cullberg G, Lundberg PA, Lindstedt G, Björntorp P. 1989 Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res. 21:391-397.
31. Lithell H, Pollare T, Vessby B. 1992 Metabolic effects of pindolol and propranolol in a double blind cross-over study in hypertensive patients. Blood Press. 1:92-101.
32. Pollare T, Lithell H, Selenius I, Berne C. 1989 Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipid metabolism in hypertensive patients. Br Med J. 298:1152-1157.
33. 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 43:455-461.
34. Carter WJ, Dang AQ, Faas FH, Lynch ME. 1991 Effects of clenbuterol on skeletal muscle mass, body composition and recovery from surgical stress in senescent rats. Metabolism. 40:855-860.
35. Coppack S. 1994 In vivo regulation of lipolysis in humans. J Lipid Res. 35:177-193.
36. Björntorp P. 1992 Metabolic abnormalities in visceral obesity: editorial. Ann Med. 24:3-5.
37. Mȧrin P, Krotkiewski M, Björntorp P. 1992 Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med. 1:329-336.
38. Xu XF, De Pergola G, Björntorp P. 1991 Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology. 128:379-382.
39. Xu X, De Pergola G, Björntorp P. 1990 The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology. 126:1229-1234.
40. Xu X, De Pergola G, Eriksson PS, et al. 1993 Postreceptor events involved in the up-regulation of beta-adrenergic receptor mediated lipolysis by testosterone in rat white adipocytes. Endocrinology. 132:1651-1657.
41. Dunaif A, Green G, Futterweit W, Dobrjansky A. 1990 Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 70:699-704.
42. Franks S. 1995 Polycystic ovary syndrome. N Engl J Med. 333:853-861.
43. Poretsky L. 1991 On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. J Clin Endocrinol Metab. 12:3-13.
44. Nestler JE, Jakubowicz DJ. 1996 Decrease in ovarian cytochrome p450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic syndrome. N Engl J Med. 335:617-623.